Clinical trials of anti–IL-21 treatment for active CD, rheumatoid arthritis, and systemic lupus erythematosus were discontinued, probably due to efficacy of IL-21 neutralization in active disease, which is consistent with our findings that therapeutic intervention for IL-21 needs to be started at the early stage of disease. The gene discussed is IL21; the disease is rheumatoid arthritis.